Stereotactic Body Radiotherapy for Oligometastases From Colorectal Cancer
Single arms prospective phase II study of SBRT for oligometastatases from colorectal cancer
Colorectal Cancer
RADIATION: Stereotactic body radiotherapy
local control assessed by RECIST, 3 years
>= Grade 3 treatment-related adverse events as assessed by CTCAE v4.0, from radiotherapy start to complete treatment 90 days|overall survival, 3 years
Single arms prospective phase II study of SBRT for oligometastatases from colorectal cancer, the primary concerns are treatment efficacy and toxicities.